Germany's Dermapharm 2025 revenue slightly misses on portfolio adjustments in parallel import business

Dermapharm Holding SE

10/03/2026 06:45

Overview

Germany-based pharmaceuticals maker's 2025 revenue slightly missed analyst expectations

Adjusted EBITDA for 2025 rose 2.9% yr/yr, driven by portfolio focus

Company expanded international footprint with acquisition of F. Trenka

Outlook

Company did not provide specific guidance for future quarters or the full year in its press release

Result Drivers

REVENUE DECLINE - Revenue fell 1.3% due to phase-out of low-margin products in Parallel import business

BRANDED PHARMACEUTICALS GROWTH - Segment saw revenue and EBITDA growth, supported by a diversified product portfolio

INTERNATIONAL EXPANSION - Acquisition of F. Trenka expanded presence in MENA region

Company press release: ID:nEQ3CyJNBa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Slight Miss*
EUR 1.17 bln
EUR 1.18 bln (5 Analysts)
FY Adjusted EBITDA
EUR 324.8 mln
FY Adjusted EBITDA Margin
27.9%
FY EBITDA
EUR 317.6 mln
FY EBITDA Margin
27.3%


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Dermapharm Holding SE is €44.00, about 15.3% above its March 9 closing price of €38.15

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)